tetano
Editor, Senior Moderator
Clin Kidney J
. 2021 Sep 28;15(2):357-359.
doi: 10.1093/ckj/sfab181. eCollection 2022 Feb.
MPO-ANCA-associated vasculitis after the Pfizer/BioNTech SARS-CoV-2 vaccination
Shota Obata[SUP] 1 [/SUP], Sumi Hidaka[SUP] 1 [/SUP], Mizuki Yamano[SUP] 1 [/SUP], Mitsuru Yanai[SUP] 2 [/SUP], Kunihiro Ishioka[SUP] 1 [/SUP], Shuzo Kobayashi[SUP] 1 [/SUP]
Affiliations
Abstract
Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has demonstrated high efficacy at preventing coronavirus disease 2019 (COVID-19) and a favorable safety profile, however it has also been reported that COVID-19 vaccines may put increase of immune-mediated disease. We herein report a case of MPO-anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis following the mRNA vaccine BNT162b2 (Pfizer/BioNTech) for COVID-19. Although the causal relationship between vaccine and ANCA-associated vasculitis is uncertain, environmental and genetic factors may have set the stage for the development of vasculitis, and the vaccine may have triggered a domino effect.
Keywords: ANCA-associated vasculitis; MPO-ANCA; SARS-CoV-2; focal necrotizing glomerulonephritis; mRNA vaccine.
. 2021 Sep 28;15(2):357-359.
doi: 10.1093/ckj/sfab181. eCollection 2022 Feb.
MPO-ANCA-associated vasculitis after the Pfizer/BioNTech SARS-CoV-2 vaccination
Shota Obata[SUP] 1 [/SUP], Sumi Hidaka[SUP] 1 [/SUP], Mizuki Yamano[SUP] 1 [/SUP], Mitsuru Yanai[SUP] 2 [/SUP], Kunihiro Ishioka[SUP] 1 [/SUP], Shuzo Kobayashi[SUP] 1 [/SUP]
Affiliations
- PMID: 35140936
- PMCID: PMC8500057
- DOI: 10.1093/ckj/sfab181
Abstract
Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has demonstrated high efficacy at preventing coronavirus disease 2019 (COVID-19) and a favorable safety profile, however it has also been reported that COVID-19 vaccines may put increase of immune-mediated disease. We herein report a case of MPO-anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis following the mRNA vaccine BNT162b2 (Pfizer/BioNTech) for COVID-19. Although the causal relationship between vaccine and ANCA-associated vasculitis is uncertain, environmental and genetic factors may have set the stage for the development of vasculitis, and the vaccine may have triggered a domino effect.
Keywords: ANCA-associated vasculitis; MPO-ANCA; SARS-CoV-2; focal necrotizing glomerulonephritis; mRNA vaccine.